Accord Healthcare Recalls Buspirone Hydrochloride Tablets Due to Manufacturing Violations
Accord Healthcare is recalling Buspirone Hydrochloride tablets due to manufacturing process deviations found during an FDA inspection. The recall affects approximately 3,784 bottles distributed in the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses, injuries, or deaths and no specific identified contamination. The hazard is a manufacturing process deviation (CGMP violation), which constitutes a precautionary action.
Plain-English summary
Accord Healthcare, Inc. is recalling Buspirone Hydrochloride Tablets USP, 10 mg, manufactured by Intas Pharmaceuticals Limited. The recall covers approximately 3,784 bottles from batch P2105472 with an expiration date of April 30, 2024.
The recall was issued following an FDA inspection that identified deviations from Current Good Manufacturing Practice (CGMP) requirements. The company is taking this precautionary action to ensure product quality and safety.
The affected products were distributed in the United States, including Puerto Rico, and Canada. Patients currently taking Buspirone Hydrochloride from the recalled batch should consult their healthcare provider or pharmacist about obtaining a replacement product.
Consumers who have this product should stop using it and contact their pharmacy or healthcare provider for guidance. Additional information about the recall is available from Accord Healthcare, Inc.
The recalled product
- Product
- BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE)
- Brand
- BUSPIRONE HYDROCHLORIDE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Batches: P2105472
- Exp. Date 4/30/2024
UPCs (2)
- 0316729289016
- 316729202169
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · BUSPIRONE HYDROCHLORIDE
- LowBuspirone Hydrochloride Tablets 5 mg Recalled for Subpotency
FDA (Drugs) · 2026-05-13
- ModerateLisinopril Tablets Recalled for Stray Amlodipine Tablet Contamination
FDA (Drugs) · 2023-11-29
- HighBuspirone Hydrochloride Tablets Recalled Due To Amlodipine Contamination Risk
FDA (Drugs) · 2023-11-29
- ModerateDrug Recall: Buspirone Tablets Over Manufacturing Process Deviations
FDA (Drugs) · 2023-05-03
- HighFDA recalls Buspirone Hydrochloride tablets for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27